BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 15625543)

  • 1. Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma.
    Kasamon YL; Jones RJ; Diehl LF; Nayer H; Borowitz MJ; Garrett-Mayer E; Ambinder RF; Abrams RA; Zhang Z; Flinn IW
    Biol Blood Marrow Transplant; 2005 Jan; 11(1):39-46. PubMed ID: 15625543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
    Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW
    Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease.
    Hahn T; Benekli M; Wong C; Moysich KB; Hyland A; Michalek AM; Alam A; Baer MR; Bambach B; Czuczman MS; Wetzler M; Becker JL; McCarthy PL
    Bone Marrow Transplant; 2005 Mar; 35(6):557-66. PubMed ID: 15665852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Intensive treatment of multiple myeloma].
    Harousseau JL
    Bull Acad Natl Med; 2003; 187(2):405-13; discussion 413-5. PubMed ID: 14556449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
    Lee CK; Barlogie B; Zangari M; Fassas A; Anaissie E; Morris C; Van Rhee F; Cottler-Fox M; Thertulien R; Muwalla F; Mazher S; Badros A; Tricot G
    Bone Marrow Transplant; 2002 Dec; 30(12):873-8. PubMed ID: 12476279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma.
    de Lima M; van Besien KW; Giralt SA; Khouri IF; Mehra R; Andersson BS; Przepiorka D; Gajewski JL; Korbling M; Champlin RE
    Bone Marrow Transplant; 1997 Jan; 19(2):121-7. PubMed ID: 9116608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
    Rodriguez R; Nademanee A; Ruel N; Smith E; Krishnan A; Popplewell L; Zain J; Patane K; Kogut N; Nakamura R; Sarkodee-Adoo C; Forman SJ
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1326-34. PubMed ID: 17162215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow transplantation in 63 adult patients with acute lymphoblastic leukemia in first complete remission.
    Vey N; Blaise D; Stoppa AM; Bouabdallah R; Lafage M; Sainty D; Cowen D; Viens P; Lepeu G; Blanc AP
    Bone Marrow Transplant; 1994 Sep; 14(3):383-8. PubMed ID: 7994259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response.
    Ganguly S; Divine CL; Deauna-Limayo D; Bodensteiner DC; Cook JD; Lewis JN; Skikne BS
    Ann Hematol; 2005 Aug; 84(8):526-31. PubMed ID: 15915350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic bone marrow transplantation in patients with follicular lymphoma: a single center study.
    Yakoub-Agha I; Fawaz A; Folliot O; Guillerm G; Quesnel B; Fenaux P; Bauters F; Jouet JP; Morschhauser F
    Bone Marrow Transplant; 2002 Aug; 30(4):229-34. PubMed ID: 12203139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study.
    Bunin N; Aplenc R; Kamani N; Shaw K; Cnaan A; Simms S
    Bone Marrow Transplant; 2003 Sep; 32(6):543-8. PubMed ID: 12953124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.
    Alyea E; Weller E; Schlossman R; Canning C; Mauch P; Ng A; Fisher D; Gribben J; Freeman A; Parikh B; Richardson P; Soiffer R; Ritz J; Anderson KC
    Bone Marrow Transplant; 2003 Dec; 32(12):1145-51. PubMed ID: 14647268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma.
    Evens AM; Winter JN; Hou N; Nelson BP; Rademaker A; Patton D; Singhal S; Frankfurt O; Tallman MS; Rosen ST; Mehta J; Gordon LI
    Br J Haematol; 2008 Feb; 140(4):385-93. PubMed ID: 18162124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies.
    Friedberg JW; Neuberg D; Gribben JG; Mauch P; Anderson KC; Soiffer RJ; Takvorian T; Fisher DC; Schlossman R; Jallow H; Kuhlman C; Ritz J; Freedman AS
    Biol Blood Marrow Transplant; 1999; 5(4):262-8. PubMed ID: 10465106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma.
    Kiss TL; Panzarella T; Messner HA; Meharchand J; Reddy V; Schimmer AD; Lipton JH
    Bone Marrow Transplant; 2003 Jan; 31(2):73-8. PubMed ID: 12621486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood or marrow transplantation for mantle cell lymphoma.
    Kasamon YL
    Curr Opin Oncol; 2007 Mar; 19(2):128-35. PubMed ID: 17272985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials?
    Sweetenham JW
    Bone Marrow Transplant; 2001 Nov; 28(9):813-20. PubMed ID: 11781640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
    Majhail NS; Weisdorf DJ; Defor TE; Miller JS; McGlave PB; Slungaard A; Arora M; Ramsay NK; Orchard PJ; MacMillan ML; Burns LJ
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1065-72. PubMed ID: 17084370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
    Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy. Ontario BMT Network, Canada.
    Schimmer AD; Jamal S; Messner H; Keating A; Meharchand J; Huebsch L; Walker I; Benger A; Gluck S; Smith A
    Bone Marrow Transplant; 2000 Oct; 26(8):859-64. PubMed ID: 11081385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.